Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity.
OBJECTIVE
To assess ocular biometric outcomes following intravitreal bevacizumab (IVB) monotherapy for retinopathy of prematurity (ROP) and compare these results with those of laser photocoagulated infants and with the ones with spontaneously regressed ROP.


METHODS
Premature infants including those who underwent IVB monotherapy (Group 1) or laser photocoagulation (Group 2) for ROP and infants with spontaneously regressed ROP (Group 3) were recruited for the study. Refractive errors and ocular biometric parameters (Axial length [AL], anterior chamber depth [ACD], and lens thickness [LT]) were measured at adjusted 1 year of age in all subjects.


RESULTS
There was no significant difference of spherical equivalent (SE) value between the groups (P = 0.781). The incidence of high myopia was 7.4% in Group 1 and 12.7% in Group 2 (P = 0.081). No infants exhibited high myopia in Group 3. LT was greater in Group 2 when compared to Group 1 and Group 3 (P = 0.011). Lower SE was significantly correlated to longer AL in Group 1 (r = -0.656, P = 0.015). There was a significant positive correlation between SE and ACD values in Group 2 (r = 0.391, P = 0.005).


CONCLUSIONS
The study showed no significant difference of SE between the groups. High myopia was only present among the treated infants either with IVB or laser. Infants who received laser treatment significantly had thicker lenses.
a Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey.
Murat
M
Gunay
b Ulucanlar Training and Research Hospital , Department of Ophthalmology , Ankara , Turkey.
Mehmet Ali
MA
Sekeroglu
c Haydarpasa Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey.
Handan
H
Bardak
a Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey.
Gokhan
G
Celik
d Trabzon Kanuni Training and Research Hospital , Department of Ophthalmology , Trabzon , Turkey.
Cenap Mahmut
CM
Esenulku
e Etlik Zubeyde Hanim Maternity and Children's Diseases Training and Research Hospital , Department of Ophthalmology , Ankara , Turkey.
Emre
E
Hekimoglu
c Haydarpasa Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey.
Yavuz
Y
Bardak
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001699:Biometry; D001724:Birth Weight; D005260:Female; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D012029:Refraction, Ocular / Q000502:physiology; D012030:Refractive Errors / Q000503:physiopathology*; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
Biometry; intravitreal injection; refraction; retinopathy of prematurity